ClinicalTrials.gg
Not yet recruitingNCT07305298Updated Feb 6, 2026

Mirabegron in Patients With Age-Related Macular Degeneration

An observational study in Dry AMD and Overactive Bladder, sponsored by University of Naples. Not yet recruiting at 1 site in Italy. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by University of Naples · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
312
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Urinary Bladder, Overactive with a site in Italy — 3 open to participants now, 3 under way, none of them phase 3. Urinary Bladder, Overactive · Italy.

Started
2026
the only one that year
Observational
5 of 30
2 open now
Registered
30th of 30
by date

Among the 30 studies in Urinary Bladder, Overactive with a site in Italy, this one is the only one that started in 2026, is one of 5 observational ones, and was the 30th registered.

Urinary Bladder, Overactive

861 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.

Browse Urinary Bladder, Overactive studies →

Open to participants now

3 of the 30 studies in Urinary Bladder, Overactive with a site in Italy are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Urinary Bladder, Overactive with a site in Italy, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if Mirabegron works to treat dry AMD in patients, aged between 50 and 80 years-old, with early or moderate dry AMD and overactive bladder.

The main question it aims to answer is:

  • Is there any change in outer retina morphology in patients treated?

Researchers will compare the safety and efficacy of mirabegron versus conventional approach (Solifenacin) to treat dry AMD in patients with dry AMD and overactive bladder.

Participants will:

  • Take Mirabegron or Solifenacin every day for 12 months
  • Visit the clinic once every 6 months for checkups and tests
03

Conditions studied

  • Dry AMD
  • Overactive Bladder
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

subjects aged between 50 and 80 years-old with early or moderate dry AMD and overreactive bladder treated with either Mirabegron or Solifenacin

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age subjects 50 and 80 years-old
  • Ability to express
  • Early or moderate dry AMD according to ARDS classification
  • Overreactive bladder
  • Visual acuity greater than BCVA 65 EDTRS letters.

Exclusion criteria

Exclusion Criteria:

    • Any medical condition which contraindicates the use of beta-agonists

      • Uncontrolled hypertension
      • Tachycardia or atrial fibrillation
      • Any allergies to the beta-agonists
      • Renal or hepatic failure
      • Long or concomitant treatment with drugs that cause lengthening of the QT interval
      • Any sign of ocular inflammation
      • xudative AMD
      • Any ongoing medical or surgical treatment for AMD (including intravitreal injections, oral supplementation of lutein, zeaxanthin and or high dietary intake of antioxidants)
      • Any other ophthalmic diseases such glaucoma, acute or chronic uveitis, advanced cataract, or any opacities of the ocular media that do not permit high-quality imaging examinations.
      • Pregnancy
      • Any condition or disease that in the opinion of the investigators may put the subject at significant risk or may interfere significantly with the subject's participation in the study (i. e. , uncontrolled or cardiovascular diseases)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
312 participants (estimated)
Patient registry
No

Groups and cohorts

  • Mirabegron arm

    Mirabegron will be administered per os at the dose of 50 mg/day for 12 months

    Drug: Mirabegron 50mg

  • Control arm

    Solifenacin will be administered per os at the dose of 5mg/day for 12 months

    Drug: Solifenacin 5mg

Interventions

  • DrugMirabegronStudies of MirabegronMirabegron pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Mirabegron (50mg/day per os) will be administered in patients with dry AMD and overactive bladder (MMirabegron arm)

  • DrugSolifenacinStudies of SolifenacinSolifenacin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Solifenacin (5mg/day per os) will be administered in control group (dry amd and overactive bladder)

06

What researchers measure

Primary outcomes

  1. Changes in outer retinal morphology using SD-OCT

    Outer nuclear layer (ONL) thickness, choroidal thickness (ChT), central macular thickness (CMT) will all be measured in micron

    Time frame: "From enrollment to the end of treatment at 12 months

  2. Changes in FAF assessing

    changes in FAF measured in micron

    Time frame: "From enrollment to the end of treatment at 12 months

Secondary outcomes

  1. mean BCVA

    Mean BCVA according to the ETDRS charts

    Time frame: From enrollment to the end of treatment at 12 months

  2. Mean macular sensitivity (MS)

    Time frame: From enrollment to the end of treatment at 12 months

Other outcomes

  1. Safety parameters

    blood pressure measured in mmHg

    Time frame: From enrollment to the end of treatment at 12 months

  2. Safety parameters

    heart frequency in bpm

    Time frame: From enrollment to the end of treatment at 12 months

  3. Safety parameters

    SpO2 (Peripheral Oxygen Saturation) in % saturation

    Time frame: From enrollment to the end of treatment at 12 months

  4. Safety parameters

    Respiratory rate in dpm

    Time frame: From enrollment to the end of treatment at 12 months

07

Study locations

1 site
08

References and documents

Publications

  • Ambrosio L, Cammalleri M, Panariello S, Califano G, Scala A, Improta G, Pisani A, Rejdak R, Ostrowski I, Filippi L, Bagnoli P, Dal Monte M, Toro MD. Mirabegron in patients with age-related macular degeneration treated for overactive bladder: a study protocol for a prospective observational non-randomized trial. Front Med (Lausanne). 2026 Mar 16;13:1761473. doi: 10.3389/fmed.2026.1761473. eCollection 2026. PubMed 41919172 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Dec 2026, 8 months later.

Of 46 non-industry observational studies under Urinary Bladder, Overactive, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 8 months is below that.

Counting every sponsor, half of 59 studies reached it within 32 months; a quarter within 17 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2025
First posted
Dec 26, 2025
StartEst.
Apr 1, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07305298
Lead sponsor
University of Naples
Collaborators
Medical University of Lublin
Responsible party
Mario Damiano Toro (Principal Investigator, MD, PhD, University of Naples) — Principal investigator
First posted
Dec 26, 2025
Start date
Apr 1, 2026 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Feb 6, 2026

Study contacts

Mario D Toro, Professor
Contact
mariodamiano.toro@unina.it
+393495158220

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion